1) Tombal B : Non-metastatic CRPC and asymptomatic metastatic CRPC : which treatment for which patient? Ann Oncol 23 : x251─258, 2012
2) Nguyen-Nielsen M, Liede A, Maeqbaek ML, et al : Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. Cancer Epidemiol 39 : 623─632, 2015
3) Smith MR, Saad F, Coleman R, et al : Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial. Lancet 379 : 39─46, 2012
4) Smith MR, Kabbinavar F, Saad F, et al : Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 : 2918─2925, 2005
5) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2016年版. メディカルレビュー社, 東京, 2016
6) Cornford P, Bellmunt J, Bolla M, et al : EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II : Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 71 : 630─642, 2017
7) Lowrance WT, Roth BJ, Kirkby E, et al : Castration-Resistant Prostate Cancer : AUA Guideline Amendment 2015. J Urol 195 : 1444─1452, 2016
8) Basch E, Loblaw DA, Oliver TK, et al : Systemic therapy in men with metastatic castration-resistant prostate cancer : American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32 : 3436─3448, 2014
9) Gillessen S, Omlin A, Attard G, et al : Management of patients with advanced prostate cancer : recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26 : 1589─1604, 2015
10) Rozet F, Roumeguere T, Spahn M, et al : Non-metastatic castrate-resistant prostate cancer : a call for improved guidance on clinical management. World J Urol 34 : 1505─1513, 2016
11) Sartor O, Eisenberger M, Kattan MW, et al : Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 18 : 549─557, 2013
12) Lecouvet FE, Geukens D, Stainier A, et al : Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer : diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25 : 3281─3287, 2007
13) Lecouvet FE, El Mouedden J, Collette L, et al : Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62 : 68─75, 2012
14) 上島修一, 加藤精二, 宋本尚俊 : 特集1前立腺がんのスクリーニングと診断 : 新規PET検査の進歩. Prostate Journal 2 : 217─223, 2015
15) Schiavina R and Martorana G : The promise of choline-PET/CT in the detection of recurrent prostate cancer : what are the limits of our investigation? Eur Urol 63 : 797─799, 2013
16) Suzuki H, Inoue Y, Fujimoto H, et al : Diagnostic performance and safety of NMK36 (trans-1-amino-3- [18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer : multicenter Phase IIb clinical trial. Jpn J Clin Oncol 46 : 152─162, 2016
17) Rowe SP, Gorin MA, Allaf ME, et al : PET imaging of prostate-specific membrane antigen in prostate cancer : current state of the art and future challenges. Prostate Cancer Prostatic Dis 19 : 223─230, 2016
18) Gotto GT, Yu C, Bernstein M, et al : Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer. Front Oncol 4 : 296, 2014